Pharmacology of (2 S,4 Z)-N-[(2 S)-2-Hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a New Potent and Selective Nonpeptide Antagonist of the Oxytocin Receptor
Authors:
- Enrico Gillio TosETEnrico Gillio Tos
- Matthias K. SchwarzMSMatthias K. Schwarz
- Anna QuattropaniAQAnna Quattropani
- Alexander ScheerASAlexander Scheer
- Marc MissottenMMMarc Missotten
- Jerôme DorbaisJDJerôme Dorbais
- Anthony NicholsANAnthony Nichols
- Francesco BorrelliFBFrancesco Borrelli
- Claudio GiachettiCGClaudio Giachetti
- Lucia GolzioLGLucia Golzio
- Paolo MarinelliPMPaolo Marinelli
- 1 July 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 306 (1) , 253-261
Abstract
We have discovered a new, potent, selective, and orally active oxytocin receptor antagonist, (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide (compound 1). We report the biochemical, pharmacological, and pharmacokinetic characterization in vitro and in vivo of this compound. Compound 1 competitively inhibits binding of [3H]oxytocin and the peptide antagonist 125I-ornithine vasotocin analog to human and rat oxytocin receptor expressed in human embryonic kidney 293-EBNA or Chinese hamster ovary cells with nanomolar potency. Selectivity against vasopressin receptor subtypes is >6-fold for V1a and >350-fold for V2 and V1b. Compound 1 inhibits oxytocin-evoked intracellular Ca2+ mobilization (IC50 = 8 nM). Compound 1 has no intrinsic agonist activity at the oxytocin receptor. Oxytocininduced contraction of isolated rat uterine strips is blocked by compound 1 (pA2 = 7.82). In anesthetized nonpregnant rats, single administration of compound 1 by i.v. or oral routes causes dose-dependent inhibition of contractions elicited by repeated injections of oxytocin with ED50 = 3.5 mg/kg i.v. and 89 mg/kg p.o., respectively. Compound 1 significantly inhibits spontaneous uterine contractions in pregnant rats near term when administered intravenously or orally. We conclude that compound 1 is a potent, selective, and orally active nonpeptide oxytocin receptor antagonist, which is a suitable candidate for evaluation as a potential tocolytic agent for the management of preterm labor.Keywords
This publication has 21 references indexed in Scilit:
- Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitroBritish Journal of Obstetrics and Gynaecology, 2001
- The Human V3 Pituitary Vasopressin Receptor: Ligand Binding Profile and Density-Dependent Signaling PathwaysEndocrinology, 1997
- The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: Implications for tocolytic therapy with oxytocin antagonistsAmerican Journal of Obstetrics and Gynecology, 1996
- Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cellsLife Sciences, 1995
- Characterization of a Novel, Linear Radioiodinated Vasopressin Antagonist: An Excellent Radioligand for Vasopressin V1a ReceptorsNeuroendocrinology, 1995
- L‐368,899, a potent orally active oxytocin antagonist for potential use in preterm laborDrug Development Research, 1993
- Synthesis of oxytocin in amnion, chorion, and decidua may influence the timing of human parturition.Journal of Clinical Investigation, 1993
- 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH29]OVT: a selective oxytocin receptor ligandEuropean Journal of Pharmacology, 1988
- Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot studyBJOG: An International Journal of Obstetrics & Gynaecology, 1987
- Endocrinology of human parturition: a reviewBJOG: An International Journal of Obstetrics & Gynaecology, 1984